Managing Autoimmune Skin Disease in Pregnancy and Lactation: Case-Based Treatment and Medication Safety

Conclusions

• For most patients with autoimmune and inflammatory skin disease, the best pregnancy outcomes come from preconception planning and maintaining disease remission on pregnancy-compatible therapy rather than stopping treatment out of fear.
• The central principle is to balance the risks of medication against the often greater risks of uncontrolled maternal disease, because active disease can worsen maternal outcomes and increase miscarriage, growth restriction, preeclampsia, and preterm birth.
• Many medications commonly used in dermatology, including hydroxychloroquine, azathioprine, corticosteroids, IVIG, tacrolimus, cyclosporine, rituximab, and several biologics, can often be continued in pregnancy when clinically necessary.
• Steroids are not strongly teratogenic, and older concerns such as cleft lip have not held up well; their main pregnancy concern is more about maternal side effects and possible late preterm birth than birth defects.
• For refractory disease in pregnancy, more advanced agents such as IVIG, some biologics, and in selected cases even JAK inhibitors or anifrolumab may be reasonable after individualized risk-benefit discussion when alternatives have failed.
• Available case series and registry data presented for tofacitinib and anifrolumab did not reveal major safety signals, suggesting that these newer agents may sometimes be used when maternal disease control is otherwise impossible.
• Breastfeeding should also be treated as part of the therapeutic plan, because lactation has measurable long-term health benefits for both mother and baby and should not be discouraged without a strong reason.
• Medication counseling during lactation must use lactation-specific sources such as LactMed, because placental safety data do not automatically apply to breast milk exposure.
• The talk argues for using the lowest effective dose of the fewest medications, avoiding subtherapeutic self-tapering, and continuing needed therapy through pregnancy and postpartum to prevent flares.
• Overall, the presentation concludes that most women with autoimmune skin disease can have good pregnancy and breastfeeding outcomes if clinicians use collaborative counseling, reliable safety resources, contraception planning, and individualized risk assessment.